liver disease has become the leading cause of non-AIDSrelated death in HIV patients [4] .
HIV/HCV-coinfected patients not receiving ART have more rapid liver fibrosis compared to HCV-monoinfected individuals [5] . Advanced fibrosis translates into poor response to HCV therapy [6] and increased rates of cirrhosis, liver failure, and hepatocellular carcinoma [2, 7] . In contrast to prior studies of HIV [8] , recent reports suggest that rates of advanced fibrosis and liver disease progression in persons with controlled HIV are similar to the rates of those with HCV alone [9, 10] .
HCV is more common among African Americans than among other racial groups [3, 7] . African Americans have poor response rates to pegylated interferon and ribavirin compared to whites (28% vs 52%, respectively) [11, 12] , independent of HCV genotype 1 [11] , which is associated with lower sustained virologic response (SVR) rates [6] . Recent studies have found earlier fibrosis stages, lower rates of cirrhosis progression [3, 11] , and higher hepatocellular carcinoma rates in African American HCV-monoinfected persons compared to whites [3] .
Coinfected African Americans are underrepresented in clinical studies [3] and their liver fibrosis has not been well characterized. Existing studies demonstrate low SVR rates [7] and significantly higher median HCV RNA levels in coinfected African Americans [13] , but have not primarily evaluated fibrosis staging. As current standard-of-care regimens have low efficacy and poor tolerability [6] , liver disease characterization is clinically utilized in treatment decisions.
The objectives of this study were to (1) measure the prevalence of early liver fibrosis in HCV monoinfected and HIV/ HCV-coinfected African American patients, and (2) determine factors associated with earlier fibrosis stages. A retrospective chart review of 154 HCV monoinfected and 180 HIV/HCV-coinfected African American patients was conducted in 5 clinics from August 2010 to March 2011. Demographics; clinical and laboratory parameters; HIV, HCV, and hepatitis B virus (HBV) data; and medications were abstracted from electronic medical records. Patients were included if they were seen at least once in a participating clinic, were at least 18 years of age, had laboratory-documented chronic HCV, and had a liver biopsy within 10 years prior to 2011. Those with a positive hepatitis B surface antigen or HBV DNA, and those who had spontaneous HCV clearance were excluded. This cross-sectional analysis included all eligible patients seen during the time period. All pathology was reported with Metavir or Knodell fibrosis staging (0-4) score. Liver biopsies were performed for routine disease staging.
METHODS

Statistical Analysis
HCV-monoinfected and HIV/HCV-coinfected persons were compared using the χ 2 test for categorical variables and Variables included age, age at time of HCV infection, sex, race/ethnicity, years since HIV diagnosis, nadir CD4, current CD4 cell count, HIV RNA, current and prior ART, HCV genotype and RNA, history of ever receiving HCV treatment, liver biopsy information (including grade, stage, and steatosis), ever and heavy alcohol use, marijuana use ever, and obesity.
Institutional review board approval was obtained from the National Institute of Allergy and Infectious Diseases, National Institutes of Health. Table 1 depicts baseline characteristics of study participants. Of the 334 African American patients evaluated, 154 (46.1%) were HCV monoinfected and 180 (53.9%) were HIV/HCV coinfected. The mean age was 54.5 ± 6.5 years. Eighty-seven patients (62.6%) had an estimated duration of HCV infection of >25 years. Patients were predominantly male (71.0%), and the primary HCV risk factor was prior intravenous drug use (66.8%). Eighty-four percent of biopsies were done in the 3 The results of the univariate and multivariate analysis to evaluate predictors of early fibrosis (stage ≤1) are described in Table 2 
RESULTS
DISCUSSION
In this study of African Americans with chronic HCV in Washington, D.C., we demonstrated that almost one-half (46.1%) had very early fibrosis and the majority (71.6%) lacked advanced disease as they had a score of ≤2 on staging of liver biopsy, despite a median infection duration of 29 years. Because African Americans respond poorly to standard HCV therapy, these data are encouraging, and individualized treatment could possibly be deferred until improved emerging treatment strategies are available. Twenty-eight percent of patients had advanced fibrosis, and would therefore require more timely consideration for treatment.
Our analysis found no significant differences between rates of early fibrosis in HCV/HIV-coinfected patients compared with those who were HCV monoinfected. Compared to the literature, we found early fibrosis stages despite the long duration of infection in many patients [8] . This finding of early fibrosis might be related to the racial composition or to the primary care setting where this study was performed, both of which contrast with other studies focusing on largely white populations at tertiary referral centers [3, 11] . Data on current HCV regimens using NS3/4A protease inhibitors demonstrate efficacy in coinfection [14] . However, trials continue to show lower SVR rates in monoinfected African Americans compared to whites, and indicate that coinfected African Americans might show similarly lower responses [14] .
The observed difference in degree of fibrosis between monoinfected and coinfected patients may be secondary to our findings that, within this cohort, coinfected patients were found to be less likely to have a history of heavy alcohol use and more likely to have received HCV treatment than monoinfected patients. The early fibrosis found in our study could be secondary to the protective effect of controlled HIV replication with effective ART use, as 81% of study patients had HIV loads below the level of detection and 94% were on ART.
Some limitations of the study are inherent in the retrospective design and a homogeneous African American population. Disease duration is an assumed estimate based on HCV acquisition within 2 years after starting intravenous drug use. Retrospective analysis of alcohol intake is likely to underestimate use. Liver biopsies are often not performed in patients who are already cirrhotic or who have certain comorbidities, leading to a selection bias in study inclusion criteria. Engaging HIV patients into care soon after their diagnosis has long been a priority, whereas monoinfected patients may not receive care until they become sick. Additionally, HIV patients are routinely HCV tested, but individuals in the general population are not usually HCV tested without a clear risk factor.
Conclusions
This study expands the current literature by focusing on liver fibrosis prevalence in an African American urban cohort with and without HIV infection, in which there is limited information regarding chronic HCV: Nearly half had early liver fibrosis, and more than half of this group with early fibrosis had HIV/HCV coinfection. Given the long median duration of infection, these African Americans may possibly have a slower disease progression, a future research focus.
Given the poor response rates, results of this study indicate that a large proportion of these patients have early disease and a long duration of infection, and therefore may not have an urgent need to start therapy, allowing treatment with moreeffective and better-tolerated future regimens.
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